Tarsus Pharmaceuticals, Inc. TARS Remainder of Fiscal Year 2024

Remainder of Fiscal Year 2024 at other companies

Bausch + LombBLCO

——

Warby ParkerWRBY

——

Other financials

Income statement

See full

Revenue$162.1M+107%

Gross profit$152.7M+109%

Operating income-$6.1M+76.7%

Net income-$7.0M+72.3%

EPS (diluted)-$0.16+75.0%

Balance sheet

See full

Cash & equivalents$104.2M-41.6%

Total debt$88.7M+22.5%

Total equity$349.0M+1.9%

Total assets$581.1M+16.1%

Cash flow

See full

Operating cash flow-$24.7M-19.4%

CapEx$5.8M+886%

Free cash flow-$30.5M-43.4%

Valuation

See full

Market cap$2.85B+41.1%

Enterprise value$2.83B+47.8%

P/S5.3×-3.3×

Profitability

See full

Gross margin42.7%—

Operating margin-9.5%-4.2pp

Net margin-9%-4.0pp

FCF margin-28%-12.6pp

Returns & leverage

See full

Return on equity-14%-5.2pp

Debt / equity0.3×0.0×

Current ratio3.7×-1.8×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear.

The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tarsus Pharmaceuticals, Inc.'s remainder of fiscal year 2024.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Tarsus Pharmaceuticals, Inc.'s remainder of fiscal year 2024?: Tarsus Pharmaceuticals, Inc. (TARS) reported remainder of fiscal year 2024 of $1.78M in Q1 2026.
How has Tarsus Pharmaceuticals, Inc.'s remainder of fiscal year 2024 changed year-over-year?: Tarsus Pharmaceuticals, Inc.'s remainder of fiscal year 2024 increased by 216.7% year-over-year, from $562K to $1.78M.